Eckert & Ziegler SE: Growth Driven by Medical Segment

Eckert & Ziegler SE has shown robust growth in Q1, particularly in its Medical segment, as outlined in a recent research by NuWays AG. The company's sales rose 11% year-over-year, adjusted for currency effects, reaching €72.9 million. The Medical segment, driven by pharmaceutical radioisotopes, reported a 21% increase in sales and a 31% rise in adjusted EBIT. This performance strengthens Medical as the core value driver, overshadowing Isotope Products.

Isotope Products faced challenges with a 7% decline in sales, attributed to weaker demand in industrial products. However, momentum regained in March supports optimistic annual targets. Looking forward, the Lu-177 therapies are expected to be a significant growth catalyst, with anticipated global sales growth and substantial investment in a production line.

With a solid balance sheet, including €124 million in cash, Eckert & Ziegler is well-positioned to pursue strategic opportunities, enhancing its standing in the radiopharmaceutical industry. The company maintains a 'Buy' recommendation with a target price of €23.